NCT06010303 2025-11-17
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT03783442 2025-07-29
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT05461794 2025-06-13
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
BeiGene
Phase 2 Terminated
NCT03957590 2025-05-02
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT04732494 2025-01-31
AdvanTIG-203
BeiGene
Phase 2 Completed
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT03469557 2024-10-23
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
BeiGene
Phase 2 Completed